QT VASCULAR LTD.
(Company Registration No. 201305911K)
(Incorporated in Singapore)
("**Company**")

REPRICING AND NEW VESTING OF CERTAIN OUTSTANDING OPTIONS GRANTED UNDER THE QT VASCULAR 2013 SHARE PLAN

The Board of Directors of QT Vascular Ltd. wishes to inform shareholders that the exercise price of certain options previously granted by the Company to its employees and directors and fully vested under the QTV 2013 Share Plan (implemented prior to the initial public offering and listing of the Company in 2014) (the "**plan**") has been repriced in accordance with the terms of the plan to be in line with the prevailing fair market value of the Company's shares ("**Repricing**"). Employees and directors holding repriced options amounting to 53,874,144 ("**Repriced Options**") (convertible into 53,874,144 new ordinary shares in the capital of the Company) will be subjected to a new vesting period.

Rationale for the Repricing

The Repricing gives the Company an opportunity to improve employee incentives and retention by adjusting the exercise price of such options to the current prevailing fair market value of the Company's shares and restarting a fresh vesting period, as permitted under the terms of plan. This will serve to create better performance incentives and retention of talent and knowledge, thereby maximising shareholders' value.

All holders of the Repriced Options will be subject to a new vesting schedule in respect of the Repriced Options (notwithstanding that the Repriced Options were already 100% vested prior to the Repricing) as follows: (1) 50% of the shares shall be immediately vested and exercisable; and (2) 50% of the shares shall vest 1/12th per month.

Financial Effects

The exercise price of the Repriced Options has been repriced from S$0.035 per option share to S$0.006 per option share ("**Repriced Exercise Price**") in accordance with the terms of the plan. There is no immediate financial impact arising from the Repriced Options although with the reduction of the exercise price of the Repriced Options, the proceeds to be received by the Company arising from exercise of the Repriced Options (if any) will be reduced accordingly.

For the avoidance of doubt the number of shares to be issued upon exercise of the Repriced Options (if any) will remain the same.

Interests of Directors and Substantial Shareholders

Holders of the Repriced Options are employees of the Company and also our Directors, Dr Eitan Konstantino, Dr Amir Belson and Mr Gregory David Casciaro who hold 28,853,184; 79,616; 1,680,000 Repriced Options under the QTV 2013 respectively who have abstained from the deliberations and approvals in relation to the Repricing.

Save for the above, none of the Directors and Substantial Shareholders has any interest (direct or indirect) in the Repricing and/or the Repriced Options.

By Order of the Board
QT VASCULAR LTD.

Eitan Konstantino
Chief Executive Officer
21 March 2019

---

*This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. ("**Sponsor**") for compliance with the Singapore Exchange Securities Trading Limited ("**SGX-ST**") Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement.*

This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made, or reports contained in this announcement.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).
